[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.205.153.63. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
June 1989

Intravitreal Tissue Plasminogen Activator Treatment of Experimental Vitreous Hemorrhage

Author Affiliations

From the Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami School of Medicine. Dr Johnson was a Heed-Knapp Fellow, 1987 to 1988.

Arch Ophthalmol. 1989;107(6):891-894. doi:10.1001/archopht.1989.01070010913040
Abstract

• Intraocular recombinant DNA human tissue-type plasminogen activator (tPA) can promote rapid resolution of intraocular fibrin clots and hyphema. The efficacy of intravitreal tPA in promoting the shortterm clearance of vitreous hemorrhage was investigated. Five treatment groups with experimentally induced vitreous hemorrhage were studied. The extent of the vitreous hemorrhage was graded based on the visibility of retinal details in each quadrant. Two weeks following intravitreal tPA injection (50 000 IU), the nonvitrectomized group and gas vitrectomy groups, each of which received a single tPA injection, showed a statistically significant reduction of the vitreous hemorrhage, although this was thought to represent only a modest clinical effect. Tractional retinal detachments were noted to develop more frequently in tPA-treated eyes as compared with controls.

×